MTAP and breast carcinoma: Integrative analysis of data from The Cancer Genome Atlas (TCGA) and Genomics of Drug Sensitivity in Cancer (GDSC), utilizing the oncoPredict R package (29), revealed that patients with breast cancer with MTAP homologous deletion exhibited heightened sensitivity to chemotherapeutic agents, particularly PARPi (Figure 2A).